Analyst Scoreboard: 12 Ratings For R1 RCM
Portfolio Pulse from Benzinga Insights
R1 RCM (NASDAQ:RCM) received mixed analyst ratings over the past three months, with a total of 12 ratings. The ratings include 3 bullish, 6 somewhat bullish, and 3 indifferent. The average 12-month price target for RCM has increased to $15.92 from $14.67, indicating a positive sentiment shift. Analysts from firms like Canaccord Genuity, Citigroup, and RBC Capital have updated their ratings and price targets, reflecting various adjustments based on R1 RCM's performance and market conditions. R1 RCM, a provider of technology-driven solutions for healthcare providers, has shown a revenue growth rate of 7.84% and a net margin of 0.24%, outperforming industry benchmarks in financial health.
March 20, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
R1 RCM received mixed analyst ratings, with an updated average 12-month price target of $15.92, indicating a positive sentiment. The company's strong financial performance, including a 7.84% revenue growth and superior net margin, supports a positive outlook.
The increase in the average price target to $15.92 from $14.67, along with the company's strong financial performance indicators such as a 7.84% revenue growth and a net margin of 0.24%, suggests analysts are optimistic about R1 RCM's future performance. This optimism, reflected in the mix of bullish and somewhat bullish ratings, is likely to have a positive short-term impact on RCM's stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100